Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Preclinical studies of sex differences: a clinical perspective.
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Treating Post-traumatic Stress Disorder in Patients with Multiple Sclerosis: A Randomized Controlled Trial Comparing the Efficacy of Eye Movement Desensitization and Reprocessing and Relaxation Therapy.
Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function.
Barcelona Pediatric MS and Related Disorders Update Meeting
Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
PML in a patient treated with dimethyl fumarate from a compounding pharmacy.
Effect of smoking on multiple sclerosis: a meta-analysis.
LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons.
Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.
Interferon-beta1b for the treatment of multiple sclerosis.
The role of pre-morbid intelligence and cognitive reserve in predicting cognitive efficiency in a sample of Italian elderly.
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Detailed results from Biogen Idec and AbbVie's pivotal Phase 3 DECIDE study further define the efficacy and safety profile of ZINBRYTA™ (daclizumab high-yield process)
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis.
Movement and structure of mitochondria in oligodendrocytes and their myelin sheaths.
Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Interferon-β1a protects neurons against mitochondrial toxicity via modulation of STAT1 signaling: Electrophysiological evidence.
Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers.
Management of women with multiple sclerosis through pregnancy and after childbirth.
The cell biology of CNS myelination.
Hematopoietic stem cell transplantation for MS: extraordinary evidence still needed.

Pages